- Active, not recruiting
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
Updated: Sep 25, 2022
EMN
European Myeloma Network
NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (CCD)

The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).
Sponsor
Collaborator
Fondazione EMN Italy Onlus
ClinicalTrials.gov Identifier: NCT01346787
Official Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
IST-CAR-506
First Posted : May 3, 2011
Click here for details on ClinicalTrials.gov